Synthetic peptide sp2 and application thereof

Abstract

A synthetic peptide sp2 has the amino acid sequence shown in SEQ ID No. 1. sp2 has obvious anti-tumor growth activity on xenograft tumours such as subcutaneous human pancreatic cancer, human cervical cancer, and human ovarian cancer in nude mice, with a dose-effect and time-effect relation; and has the effect of delaying metastasis and prolonging the survival time of nude mouse having in situ transplantation of human pancreatic cancer and lung adenocarcinoma. After the animals were given intravenous injection of sp2 at a dose of 2000 mg/kgBW, no toxicity reaction and death were observed. The applications of sp2 also include: (1) preventing and/or treating of tumor; (2) inhibiting proliferation and/or growth and/or invasion of tumor cells; (3) enhancing the anti-tumor immune response; (4) inducing tumor cell differentiation; (5) preparing anti-tumor drugs; (6) inhibiting tumor telomerase activity; and (7) regulating the tumor cell cycle.

1 . A synthetic peptide sp2 consisting of an amino acid sequence of SEQ ID NO.1. 
     
     
         2 . An application of the synthetic peptide sp2 according to  claim 1  in any one of the following (1) to (7): (1) preventing and/or treating of tumors; (2) inhibiting proliferation and/or growth of tumor cells; (3) enhancing anti-tumor immune response; (4) inducing tumor cell differentiation; (5) preparing anti-tumor drugs; (6) inhibiting tumor telomerase activity; and (7) regulating tumor cell cycle. 
     
     
         3 . The application of the synthetic peptide sp2 according to  claim 2 , wherein one of the applications is to prepare the anti-tumor drugs of human pancreatic cancer in situ, human cervical cancer, human ovarian cancer, human osteosarcoma, human lung adenocarcinoma, and human poorly differentiated pregastric cancer. 
     
     
         4 . The application of the synthetic peptide sp2 according to  claim 3 , wherein cell lines of the tumor are respectively human pancreatic cancer in situ BxPC-3, human cervical cancer SiHa, human ovarian cancer A2780, human osteosarcoma MG-63, human lung adenocarcinoma A549, and human poorly differentiated pregastric cancer BGC-823 . 
     
     
         5 - 6 . (canceled)